Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: December 14, 2007

CNSI and NanoPacific Holdings Announce a Partnership to Develop and Commercialize Nanotechnology

(Nanowerk News) On the day of its official inauguration, the California NanoSystems Institute (CNSI) at UCLA and NanoPacific Holdings, Inc. (NPH) announce a partnership to commercialize a mechanized nanoparticle-based technology that could mean prolonged lives of enhanced quality for millions of cancer sufferers. Under the terms of the partnership, NPH will receive an exclusive license to key intellectual property owned by UCLA and developed within the Nano Machine Center (NMC) at the CNSI. The newly formed company will provide funding for further research to be performed in the NMC to broaden the scope of the technology in order to encompass a diverse range of applications.
The first application which will be pursued under the partnership will be aimed at targeting the delivery of known, trusted and FDA approved chemotherapeutic agents in much reduced doses to cancer cells. Because of their unique properties, these mechanized nanoparticles can be pre-programmed to seek out cancer cells specifically while sparing other rapidly growing cells (e.g., hair follicles and stomach linings) in the body from highly undesirable side effects, such as hair loss and chronic diarrhea. In addition, these robotic-like nanoparticles will enable the triggered release of cancer drugs that are presently difficult to administer intravenously to patients because of their low solubilities in the blood stream. Significant applications of the new technology are also anticipated in other major commercial arenas, for example, scent and cosmetics, food products, environmental remediation, construction materials, and defense.
The delivery mechanism consists of porous nanoparticles, capable of storing and selectively releasing small drug molecules via nanoscale gates that can be opened and closed at will on the surface of the nanoparticles. In this way drugs can be loaded and unloaded in a selective manner in different environments. By equipping the nanoparticle surfaces with specific tags to preferentially target cancer cells, diseased cells can be destroyed selectively without affecting healthy ones, thus reducing drug toxicity dramatically. The concept is a simple one that is open to infinite variation.
“This partnership is a prime example of how the CNSI will fulfill its mission,” said UCLA Chancellor Gene D. Block. “Working with industry to bring new developments in technology and biotechnology into the marketplace for the benefit of the people of California is exactly why the CNSI was established.”
The California NanoSystems Institute fosters interdisciplinary collaborations in nanoscience and nanotechnology research and facilitates partnerships with private industry, fueling economic development and the social well-being of California, the United States and the world.
“This collaboration underscores many key objectives of the CNSI. The faculty members involved in the Nano Machine Center at CNSI are developing exciting technologies which have the potential to generate major advances in healthcare and medical treatment,” said Leonard H. Rome, CNSI Interim Director and Senior Associate Dean of Research for the David Geffen School of Medicine at UCLA.
“We are looking forward to launching this collaboration and working in a seamless fashion with UCLA and the world-class scientific team at the CNSI to develop and commercialize nano technology,” said Joseph A. Boystak, Chairman & Co-CEO of NanoPacific Holdings. “We intend to prioritize and aggressively pursue multiple applications in the medical, consumer, environmental and industrial sectors and in doing so we envision spawning a series of companies and partnerships with important commercial partners to accelerate the roll out of this technology.”
“I am delighted to be part of the team that provides a bridge from the cutting-edge research being done at the CNSI to industry. This step is a profound one for NanoPacific Holdings and UCLA as we move forward in the dynamic world of nano technology,” said Michael B. Flesch, Vice Chairman and Co-CEO of NanoPacific Holdings. “This collaboration also underscores the value and importance of academic/commercial partnerships.”
“The breadth of commercial applications for technologies arising from university nanotechnology research is enormous and UCLA is excited to be working with the team of business and scientific talent at NanoPacific to bring nanotech-enabled products to market to benefit patients and society at large,” said Earl Weinstein, PhD and Assistant Director of Technology Transfer at UCLA. “This startup is part of a growing number of high tech companies resulting from research at UCLA that have chosen to establish themselves locally, which also benefits the burgeoning Los Angeles tech cluster. We look forward to a long and productive relationship with them,” Weinstein added.
The Nano Machine Center for Targeted Delivery and On-Demand Release of Active Substances is a recently established multidisciplinary research center at the California NanoSystems Institute at UCLA. The Center is co-directed by four Professors who have expertise in different chemical, biological and medical disciplines and who have collaborated in multiple combinations for the past decade. Dr. Jeffrey Zink, Professor of Chemistry and Biochemistry, studies mechanically, electrically and optically functional silica-based nanostructured materials; Dr. Fraser Stoddart, Professor of Chemistry and Biochemistry, has pioneered the design and template-directed synthesis of supramolecular and molecular machines; Dr. Fuyu Tamanoi, Professor of Microbiology, Immunology and Molecular Genetics, Director of Signal Transduction and Therapeutics program at the Jonsson Comprehensive Cancer Center, studies signal transduction and the development of anticancer drugs; and Dr. Andre Nel, Professor of Medicine and the Chief of the Division of Nanomedicine, is an expert on nanoparticles and their interaction with biological substrates at the nano/bio interface. The team has already co-authored seven papers this year covering the topics of light activated release, pH-activated release, anticancer drug delivery and cellular uptake mechanisms of nanoparticles, which are all critical to the new partnership with NanoPacific Holdings.
NanoPacific Holdings, Inc. is a privately-held holding company based in Los Angeles solely focused on the development and commercialization of nanotechnology emerging from its strategic relationship with UCLA/CNSI.
The California NanoSystems Institute (CNSI) was established in 2000 as a joint enterprise between UCLA and UC Santa Barbara, with $100 million in funding coming from the state of California and an additional $250 million in federal research grants and industry funding. The CNSI is a multidisciplinary research institute whose mission is to encourage university collaboration with industry and enable the rapid commercialization of discoveries in nanosystems. CNSI members at UCLA include some of the world’s preeminent scientists working in five targeted areas of nanosystems-related research: renewable energy; environmental nanotechnology and nanotoxicology; nanobiotechnology and biomaterials; nanomechanical and nanofluidic systems; and nanoelectronics, photonics and architectonics. For additional information, visit the CNSI Web site at www.cnsi.ucla.edu.
UCLA is California’s largest university, with an enrollment of nearly 37,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university’s 11 professional schools feature renowned faculty and offer more than 300 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.
Source: UCLA